ArticleStroke2021
Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Stroke, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06037889 (Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease), which is not on this map. Cited by 45 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Altered methylation pattern in EXOC4 is associated with stroke outcome: an epigenome-wide association study.Clinical epigenetics · 2022Pooled it
- Risk prediction models for malignant cerebral edema after endovascular therapy in patients with acute anterior circulation large vessel occlusion stroke: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Prediction models for early neurological deterioration in patients with acute ischemic stroke: a systematic review and critical appraisal.Frontiers in neurologyPooled it
- Plasma choline and betaine and neurological function trajectory after acute ischemic stroke.BMC neurology · 2026Trial
- Twenty-Four-Hour Post-Thrombolysis NIHSS Score As the Strongest Prognostic Predictor After Acute Ischemic Stroke: ENCHANTED Study.Journal of the American Heart Association · 2024Trial
- Discharge NIHSS scores are predictive of poor 3-month outcomes in patients with acute Ischemic stroke receiving intravenous thrombolysis.Annals of medicine · 2026Article
- Predicting Functional Prognosis in Supratentorial Stroke Using [¹⁸F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography.Yonsei medical journal · 2026Article
- National survey of clinical practices and perspectives in the management of ischaemic stroke patients with minor neurological deficits.Acta neurologica Belgica · 2026Article
- Efficacy and safety of Qingre Huatan Formula for the prevention of early neurological deterioration in patients with acute ischemic stroke (QUIET): rationale and design for a randomized double-blind placebo-controlled study.Frontiers in medicine · 2026Article
- Machine Learning-Based Risk Stratification for Symptomatic Intracranial Hemorrhage and 3-Month Prognosis following Intravenous Thrombolysis.Cerebrovascular diseases extra · 2026Article
- Clinical outcomes of patients with unsuccessful mechanical thrombectomy versus best medical management of medium vessel occlusion stroke in the middle cerebral artery territory.Journal of neurointerventional surgery · 2025Article
- Article
- Artifical intelligence-powered delta-NIHSS-based model for predicting recurrence, disability and mortality after acute ischaemic strokes (DISCO): a modelling study.EClinicalMedicine · 2025Article
- How achievement of a stroke care pathway is associated with functional outcome after stroke: a national, register-based study.BMC health services research · 2025Article
- Observational
- Predictive Model for Early Neurological Deterioration in Acute Ischemic Stroke Utilizing Novel Thrombotic Biomarkers.Brain and behavior · 2025Article
- Analyzing the serum biochemical factors that influence early neurological deterioration in ischemic Stroke patients and developing a nomogram prediction model.Journal of medical biochemistry · 2025Article
- Identifying the predictors of ultra early neurological improvement and its role in functional outcome after endovascular thrombectomy in acute ischemic stroke.Frontiers in neurology · 2025Article
- Explainable machine learning model for predicting the outcome of acute ischemic stroke after intravenous thrombolysis.Frontiers in neurology · 2025Article
- Optimal 24-h NIHSS threshold of ⩽9 predicts 90-day outcomes after posterior circulation thrombectomy: ANGEL-ACT Registry Insights.Therapeutic advances in neurological disorders · 2025Article
Corrections and comments
- Commented on by
Authors and funding
51 authors at 20 institutions in 8 countries.
Laura HeitschDivision of Emergency Medicine (L.H.), Washington University School of Medicine, St Louis, MO.
Laura IbanezDepartment of Psychiatry (L.I., C. Cruchaga), Washington University School of Medicine, St Louis, MO.
Caty CarreraNeurovascular Research Laboratory and Neurovascular Unit, Vall d'Hebron Institute of Research (VHIR) (C. Carrera, A.B., I.F.-C., J.M.), Universitat Autonoma de Barcelona, Spain.
Michael M BinkleyDivision of Emergency Medicine (L.H.), Washington University School of Medicine, St Louis, MO.
Daniel StrbianDepartment of Neurology, Helsinki University Hospital, Finland (D.S., T.T.).
Turgut TatlisumakDepartment of Neurology, Helsinki University Hospital, Finland (D.S., T.T.).
Alejandro BustamanteNeurovascular Research Laboratory and Neurovascular Unit, Vall d'Hebron Institute of Research (VHIR) (C. Carrera, A.B., I.F.-C., J.M.), Universitat Autonoma de Barcelona, Spain.
Marc RibóDepartment of Neurology, Hospital Universitari Vall d"Hebron (C. Carrera, A.B., M.R., C.M.), Universitat Autonoma de Barcelona, Spain.
Carlos MolinaDepartment of Neurology, Hospital Universitari Vall d"Hebron (C. Carrera, A.B., M.R., C.M.), Universitat Autonoma de Barcelona, Spain.
Antoni DávalosDepartment of Neurology, Hospital Universitari Germans Trias I Pujol, Badalona, Spain (A.D.).
Elena López-CancioDepartment of Neurology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain (E.L.-C.).
Lucia Muñoz-NarbonaInstitut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain (L.M.-N., C.S.-T., E.G.-S., J.R., J.J.-C.).
Carol Soriano-TárragaInstitut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain (L.M.-N., C.S.-T., E.G.-S., J.R., J.J.-C.).
Eva Giralt-SteinhauerInstitut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain (L.M.-N., C.S.-T., E.G.-S., J.R., J.J.-C.).
Victor ObachDepartment of Neuroscience, Hospital Clinic, University of Barcelona and August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain (V.O.).
Agnieszka SlowikDepartment of Neurology (A.S., J.P., J.D.), Jagiellonian University Medical College, Krakow, Poland.
Joanna PeraDepartment of Neurology (A.S., J.P., J.D.), Jagiellonian University Medical College, Krakow, Poland.
Katarzyna Lapicka-BodziochDepartment of Neurogenetics (K.L.-B.), Jagiellonian University Medical College, Krakow, Poland.
Justyna DerbiszDepartment of Neurology (A.S., J.P., J.D.), Jagiellonian University Medical College, Krakow, Poland.
Tomás SobrinoClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela, Hospital Clinico Universitario, Universidade de Santiago de Compostela, Spain (T.S., J.C., F.C., E.R.-C., S.A.-R.).
José CastilloClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela, Hospital Clinico Universitario, Universidade de Santiago de Compostela, Spain (T.S., J.C., F.C., E.R.-C., S.A.-R.).
Francisco CamposClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela, Hospital Clinico Universitario, Universidade de Santiago de Compostela, Spain (T.S., J.C., F.C., E.R.-C., S.A.-R.).
Emilio Rodríguez-CastroClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela, Hospital Clinico Universitario, Universidade de Santiago de Compostela, Spain (T.S., J.C., F.C., E.R.-C., S.A.-R.).
Susana Arias-RivasClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela, Hospital Clinico Universitario, Universidade de Santiago de Compostela, Spain (T.S., J.C., F.C., E.R.-C., S.A.-R.).
Tomas SeguraClinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela, Hospital Clinico Universitario, Universidade de Santiago de Compostela, Spain (T.S., J.C., F.C., E.R.-C., S.A.-R.).
Gemma Serrano-HerasDepartment of Neurology, Hospital Universitario de Albacete, Spain (T.S., G.S.-H.).
Cristófol Vives-BauzaDepartment of Neurology, Son Espases University Hospital, IdISBa, Palma de Mallorca, Spain (C.V.-B., R.D.-N., S.T., C.J.).
Rosa Díaz-NavarroDepartment of Neurology, Son Espases University Hospital, IdISBa, Palma de Mallorca, Spain (C.V.-B., R.D.-N., S.T., C.J.).
Silva TurDepartment of Neurology, Son Espases University Hospital, IdISBa, Palma de Mallorca, Spain (C.V.-B., R.D.-N., S.T., C.J.).
Carmen JimenezDepartment of Neurology, Son Espases University Hospital, IdISBa, Palma de Mallorca, Spain (C.V.-B., R.D.-N., S.T., C.J.).
Joan Martí-FàbregasDepartment of Neurology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain (J.M.-F., R.D.-M.).
Raquel Delgado-MederosDepartment of Neurology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain (J.M.-F., R.D.-M.).
Juan ArenillasDepartment of Neurology, Hospital Clinico Universitario de Valladolid, Spain (J.A.).
Jerzy KrupinskiDepartment of Neurology, Hospital Mutua de Terrassa, Spain (J.K., I.F.-C.).
Natalia CullellStroke Pharmacogenomics and Genetics, Fundacio Docencia I Recerca Mutua de Terrassa, Spain (N.C., E.M., J.C.-M., I.F.-C.).
Nuria P Torres-AguilaStroke Pharmacogenomics and Genetics, Sant Pau Institute of Research, Sant Pau Hospital, Barcelona, Spain (N.C., N.P.T.-A., E.M., J.C.-M.).
Elena MuiñoStroke Pharmacogenomics and Genetics, Fundacio Docencia I Recerca Mutua de Terrassa, Spain (N.C., E.M., J.C.-M., I.F.-C.).
Jara Cárcel-MárquezStroke Pharmacogenomics and Genetics, Fundacio Docencia I Recerca Mutua de Terrassa, Spain (N.C., E.M., J.C.-M., I.F.-C.).
Francisco MonicheDepartment of Neurology, Hospital Universitario Virgen del Rocio, Sevilla, Spain (F.M., J.A.C.).
Juan A CabezasDepartment of Neurology, Hospital Universitario Virgen del Rocio, Sevilla, Spain (F.M., J.A.C.).
Andria L FordDepartment of Neurology (L.H., M.M.B., A.L.F., R.D., J.-M.L.), Washington University School of Medicine, St Louis, MO.
Rajat DharDepartment of Neurology (L.H., M.M.B., A.L.F., R.D., J.-M.L.), Washington University School of Medicine, St Louis, MO.
Jaume RoquerInstitut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain (L.M.-N., C.S.-T., E.G.-S., J.R., J.J.-C.).
Pooja KhatriDepartment of Neurology, University of Cincinnati, OH (P.K.).
Jordi Jiménez-CondeInstitut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain (L.M.-N., C.S.-T., E.G.-S., J.R., J.J.-C.).
Israel Fernandez-CadenasNeurovascular Research Laboratory and Neurovascular Unit, Vall d'Hebron Institute of Research (VHIR) (C. Carrera, A.B., I.F.-C., J.M.), Universitat Autonoma de Barcelona, Spain.
Joan MontanerNeurovascular Research Laboratory and Neurovascular Unit, Vall d'Hebron Institute of Research (VHIR) (C. Carrera, A.B., I.F.-C., J.M.), Universitat Autonoma de Barcelona, Spain.
Jonathan RosandInstitut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain (L.M.-N., C.S.-T., E.G.-S., J.R., J.J.-C.).
Carlos CruchagaDepartment of Psychiatry (L.I., C. Cruchaga), Washington University School of Medicine, St Louis, MO.
Jin-Moo LeeDepartment of Neurology (L.H., M.M.B., A.L.F., R.D., J.-M.L.), Washington University School of Medicine, St Louis, MO.
International Stroke Genetics Consortium
Hospital de Sant Pau · ESUniversidade de Santiago de Compostela · ESWashington University in St. Louis · USHospital Del Mar · ESHospital Universitario Son Espases · ESJagiellonian University · PLUniversitat Autònoma de Barcelona · ESHelsinki University Hospital · FIHospital del Mar Research Institute · ESHospital Universitario Virgen del Rocío · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Clínico Universitario de Valladolid · ESHospital General Universitario de Albacete · ESHospital Universitari Germans Trias i Pujol · ESHospital Universitario Central de Asturias · ESMACOM (United States) · USUniversity Hospital Mútua de Terrassa · ESUniversity of Cincinnati · USUniversity of Manchester · GBVall d'Hebron Institut de Recerca · ES
Funding
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1MResearch Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 2020 to 2026
$28.7MMR-Derived Cerebral Oxygen Metabolism underlying Ischemic Vulnerability in Sickle Cell DiseaseR01HL129241 · NHLBI · WASHINGTON UNIVERSITY · PI Hongyu An, Robert A Campbell · 2015 to 2026
$6.6MGenetic Architecture of Acute Human Brain IschemiaR01NS085419 · NINDS · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, LEE, JIN-MOO · 2014 to 2018
$2.8MMid-America Regional Coordinating Center (MARCC)U24NS107230 · NINDS · WASHINGTON UNIVERSITY · PI Andria Lee Ford, Peter David Panagos · 2018 to 2026
$2.8MGENETICS OF EARLY NEUROLOGICAL INSTABILITY AFTER ISCHEMIC STROKE (GENISIS)K23NS099487 · NINDS · WASHINGTON UNIVERSITY · PI HEITSCH, LAURA · 2017 to 2021
$996kGENETICS AND PREDICTION OF CEREBRAL EDEMA AFTER HEMISPHERIC STROKEK23NS099440 · NINDS · WASHINGTON UNIVERSITY · PI DHAR, RAJAT · 2017 to 2021
$890kNHLBI NIH HHS R01 HL129241NIA NIH HHS P30 AG066444NIA NIH HHS P50 AG005681NINDS NIH HHS K23 NS099440NINDS NIH HHS K23 NS099487NINDS NIH HHS R01 NS085419NINDS NIH HHS U24 NS107230
Abstract
background and purposeLarge-scale observational studies of acute ischemic stroke (AIS) promise to reveal mechanisms underlying cerebral ischemia. However, meaningful quantitative phenotypes attainable in large patient populations are needed. We characterize a dynamic metric of AIS instability, defined by change in National Institutes of Health Stroke Scale score (NIHSS) from baseline to 24 hours baseline to 24 hours (NIHSS
methodsPatients with NIHSS prospectively recorded within 6 hours after onset and then 24 hours later were enrolled in the GENISIS study (Genetics of Early Neurological Instability After Ischemic Stroke). Stepwise linear regression determined variables that independently influenced ΔNIHSS
resultsFor 2555 patients with AIS, median baseline NIHSS was 9 (interquartile range, 4-16), and median ΔNIHSS
conclusionsThe dynamic phenotype, ΔNIHSS
Indexed as
Ischemic StrokeRecovery of FunctionSeverity of Illness IndexAgedAged, 80 and overFemaleHumansMaleMiddle Agedgenome-wide association studyphenotypepopulationstroke, ischemic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06037889ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.